Myeloblative therapy with autologous haematopoietic stem cell support as consolidation of first remission in acute myeloid leukaemia – very long follow‐up

A recently published population-based study showed an improvement in 5-year relative survival of patients with acute myeloid leukaemia (AML) presenting between 1971 and 2006 (Shah et al, 2013). In the light of that analysis, results for 285 younger adults with AML treated during that time period are presented, with a current minimum follow-up of 14 years, highlighting the role of intensive consolidation. A strategy of using myeloablative therapy...